Estimation of cost-of-illness in patients with psoriasis in Switzerland

Swiss Medical Weekly

Volumn 140, Issue 5-6, 2010, Pages 85-91

  Navarini, Alexander A ^a   Laffitte, Emanuel ^b   Conrad, Curdin ^a   Piffaretti, Paolo ^c   Brock, Elisabeth ^d   Ruckdaeschel, Stephan ^d   Trüeb, Ralph M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Wyeth Pharmaceuticals AG   (Switzerland)

^d HealthEcon Ltd   (Switzerland)

Author keywords

Cost of illness; Moderate to severe psoriasis; Quality of life; Switzerland

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT;

ADULT; AMBULATORY CARE; ARTICLE; BATH; BODY SURFACE; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL PATIENT; HUMAN; HYPOTHESIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL SERVICE; OUTPATIENT; PATIENT CARE; PRESCRIPTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SKIN CARE; SWITZERLAND;

EID: 76649106409     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Poyner T, Wall A, Adnitt P, A. M. Economic impact of psoriasis treatment on the patient and on the National Health Service. J Dermatol Treatment. 1999:25-9.
2. Galadari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol. 2001;15:290-1.
3. Finzi AF, Mantovani LG, Belisari A. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol. 2001;15:320-4.
4. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-60.
5. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol. 2002;43:255-61.
6. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20:1929-36.
7. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3:511-8.
8. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212:137-44.
9. Schoffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5:209-18.
10. Traupe H, Robra B. Psoriasis. Gesundheitsberichterstattung des Bundes 2002.
11. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. Br J Dermatol. 1990;123:751-6.
12. Documed. Arzneimittelkompendium der Schweiz. In: Documed, ed. 2005.
13. Press release 0350-0703-10 from March 19th, 2007. Federal Statistical Office (FSO) of Switzerland.
14. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146:1006-16.
15. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135:533-7.
16. Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001;15:20-3.
17. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-8.
18. Amblard P. Psoriasis. Diagnosis, clinical course, prognosis, treatment. Rev Prat. 1993;43:229-31.
19. Crown WH. The cost of psoriasis. Manag Care. 2003;12:10-3; discussion 20-1.
20. Krueger G, Koo J, Lebwohl M, Menter A, Stern Rs, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
21. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is comunon, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-9.
22. The Burden of Skin Diseases 2005. In: Prepared for The Society for Investigative Dermatology and The American Academy of Dermatology Association: LEWIN GROUP 2005.
23. Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multicenter clinical trial. J Dermatol. 1999;26:210-5.
24. Blumberg HH, Fuller C, Hare AP. Response Rates in Postal Surveys. Public Opinion Quarterly. 1974;38:113-23.
25. Eaker S, Bergstrom R, Bergstrom A, Adami HO, Nyren O. Response rate to mailed epidemiologic questionnaires: a population-based randomized trial of variations in design and mailing routines. Am J Epidemiol. 1998;147:74-82.